BioAxone BioSciences celebrates official opening of clinical and research operations in Cambridge, Mass.
BioAxone BioSciences, a privately held biotechnology company, today celebrated the opening of its scientific and clinical headquarters in Cambridge, Mass., as well as its selection this week by Windhover Conferences as one of the “Top Ten” Neuroscience Companies for Partnership. The company’s celebration was held today with local officials and industry leaders. Attending the event were BioAxone CEO, Dr. Lisa McKerracher; Massachusetts Life Sciences Center Vice President for Communications and Marketing, Angus McQuilken; MassBio Director of Economic Development and Global Affairs, Peter Abair; Founder of Massachusetts Walks Again, Dr. Eric Ruby; and Boston Mayor Thomas Menino’s Commissioner for Persons with Disabilities, Kristen McCosh.
BioAxone, headquartered in Florida, is developing a protein therapeutic drug called Cethrin to improve patient recovery from spinal cord injury. Its scientific and clinical headquarters will be located at the Cambridge Innovation Center in Cambridge, Mass., which was selected for its concentration of life sciences companies, availability of walk-in wet-lab incubator space and its skilled workforce. Dr. McKerracher will be starting operations in Cambridge, with plans to hire 12 employees by 2013.
Dr. McKerracher, of BioAxone, said, “I am pleased that Cethrin and BioAxone’s leadership in the field of spinal cord injury have been recognized by Elsevier Business Intelligence and Windhover Conferences. Now that BioAxone has joined the Massachusetts life sciences community, we look forward to reporting progress on Cethrin and collaborating with members of the world’s leading life sciences cluster to continue to develop novel drugs for unmet needs in the field of neurotrauma.”
“Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences,” said Governor Deval Patrick. “We welcome BioAxone to Massachusetts and look forward to their contributions to our thriving life sciences community.”
Traumatic spinal cord injury affects more than 12,000 Americans each year, mainly from motor vehicle accidents. Approximately 70 percent of patients suffer injuries to the cervical spinal cord, which leads to quadriplegia and dependence on care for daily living. There are no approved drugs to treat spinal cord injury. The only current treatment for SCI is surgery and rehabilitation.
Cethrin’s mechanism of action is to facilitate plasticity and rewiring of pathways damaged by spinal cord injury. Studies on axon regeneration and recovery in rodents have revealed that “learning” can occur in spinal cord circuits and the spinal cord is not hard wired. Cethrin facilitates axon regeneration and stimulates plasticity and is the only drug in development that targets multiple inhibitory signals to promote regenerative repair after spinal cord injury.
“On behalf of the Center, we would like to warmly welcome BioAxone to Massachusetts,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick’s 10-year, $1 billion Life Sciences Initiative. “BioAxone’s drug development program is a source of hope for individuals suffering from traumatic spinal cord injuries, and the company is a welcome addition to our thriving life sciences community in Massachusetts. We are so pleased that that BioAxone selected Massachusetts as the best place for the company’s scientific and clinical headquarters!”
“Massachusetts’ strength is in our density of life sciences companies, academic institutions, medical centers and organizations that support the cluster’s success,” said Abair, of MassBio. “We’re thrilled to welcome BioAxone to the Massachusetts supercluster, and celebrate the number of small, innovative research companies who are setting up shop in Kendall Square.”
BioAxone’s clinical program to develop Cethrin has been selected by Windhover conferences as one of the “Top Ten” neuroscience partnership opportunities to watch. David Cassak, Vice President, Content, Windhover Conferences explained that “to be selected as a winner, BioAxone has met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.”
Also recognized at the event were other companies that have recently located offices in the Cambridge Innovation Center, including Alacrita, Arrayjet and Qserve Group.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.